Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

NCT07254858 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

302

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2- Breast Cancer

Interventions

RADIATION: Neoadjuvant radiotherapy
DRUG: Neoadjuvant Chemotherapy (NACT)
DRUG: Immunotherapy (Sintilimab)

Sponsor

First Affiliated Hospital of Wenzhou Medical University